Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Q44368041)

2 December 2017

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (English)

1 reference

2 December 2017

metastatic breast cancer

1 reference

1

1 reference

2 December 2017

Elżbieta Senkus-Konefka

object named as

E Senkus-Konefka

ESMO Guidelines Working Group

2

0 references

6

object named as

ESMO Guidelines Working Group

1 reference

2 December 2017

L Fallowfield

3

1 reference

2 December 2017

A Costa

4

1 reference

2 December 2017

M Castiglione

5

1 reference

2 December 2017

1 May 2010

1 reference

2 December 2017

1 reference

2 December 2017

21 Suppl 5

1 reference

2 December 2017

v15-9

1 reference

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

2 December 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ160

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ160

1 reference

2 December 2017

1 reference